Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for Hard-to-Treat blood cancers

NCT ID NCT02362035

Disease control Sponsor: Acerta Pharma BV Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims to control the disease rather than cure it, as ongoing treatment may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

161 people

The number who actually took part.

Started

Feb 2015

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: * Diagnosis of a hematologic malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO). * Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1. * Agreement to use contraception during the study and for 90 days after the last dose of ACP-196 or 120 days after the last dose of pembrolizumab, if sexually active and able to bear or beget children. * Completion of all therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥ 4 weeks before the start of study therapy. * ANC ≥ 0.5 x 10\^9/L or platelet count ≥ 50 x 10\^9/L unless due to disease involvement in the bone marrow. Main Exclusion Criteria: * A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk. * Central nervous system (CNS) involvement by lymphoma/leukemia * Any therapeutic antibody within 4 weeks of first dose of study drugs. * Total bilirubin \> 1.5 x ULN; and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3.0 x ULN. * Estimated creatinine clearance of \< 30 mL/min, calculated using the formula of Cockcroft and Gault (140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burkitt lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Burkitt lymphoma follicular lymphoma hairy cell leukemia Hodgkins lymphoma indolent B-cell non-Hodgkin lymphoma mantle cell lymphoma marginal zone lymphoma plasma cell myeloma primary mediastinal large B-cell lymphoma Richter transformation Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Burkitt lymphoma CLL Follicular lymphoma ( FL) Hairy cell leukemia Hodgkin lymphoma Indolent non-Hodgkin lymphoma Mantle cell lymphoma (MCL) Marginal zone lymphomas Mediastinal large B cell lymphoma Multiple myeloma Richter's syndrome Small lymphocytic lymphoma (SLL) Waldenström macroglobulinemia

Contacts and locations

Locations

  • Research Site

    Tucson, Arizona, 85704, United States

  • Research Site

    Los Angeles, California, 90095, United States

  • Research Site

    Denver, Colorado, 80218, United States

  • Research Site

    Washington D.C., District of Columbia, 20007, United States

  • Research Site

    Niles, Illinois, 60714, United States

  • Research Site

    Boston, Massachusetts, 2215, United States

  • Research Site

    Rochester, Minnesota, 55905-0001, United States

  • Research Site

    Omaha, Nebraska, 68198-7680, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Greenville, South Carolina, 29605, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Dallas, Texas, 75246, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    San Antonio, Texas, 78217, United States

  • Research Site

    Tyler, Texas, 75702, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Roanoke, Virginia, 24014, United States

  • Research Site

    Vancouver, Washington, 98684, United States

  • Research Site

    Yakima, Washington, 98902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.